Literature DB >> 7192124

Metabolic and pharmacokinetic studies with fenbufen in man.

F S Chiccarelli, H J Eisner, G E Van Lear.   

Abstract

Single oral doses of 600 mg of 14C-labelled gamma-oxo(1,1'-biphenyl)-4-butanoic acid (fenbufen) were administered to three male volunteers. Additional male and female subjects received single (500-700 mg) or multiple (300-400 mg b.i.d.) doses of non-isotopically labelled drug. Fenbufen was rapidly absorbed from the gastroiintestinal tract to the extent of at least 78%. Food reduced the rate but not the extent of absorption. Peak serum concentrations of total drug related compounds were reached by 2 h, at which time fenbufen accounted for only 11% of these substances. The remaining drug related material consisted of two metabolites: gamma-hydroxy(1,1'-biphenyl)-4-butanoic acid and (1,1'-biphenyl)-4-acetic acid. Steady state serum concentrations were reached within a week with multiple dosing regimens. The ratio of fenbufen to its circulating metabolites did not change over a month of daily dosing. Only traces of fenbufen and metabolites were present in the cellular components of blood or in human milk, but significant amounts (concentrations one-third those in serum) were measured in the synovial fluid of arthritic patients. Fenbufen and its circulating metabolites were highly bound (> 98%) to human serum in vitro, but at therapeutic levels showed very small or no effects on the serum binding of various other commonly used drugs. Concomitant administration of fenbufen and acetylsalicylic acid (ASA) resulted in decreased serum concentration of fenbufen and its metabolites compared to those obtained from fenbufen administration alone. In addition to the serum metabolites, three more transformation products were identified in urine: 4'-hydroxy(1,1'-biphenyl)-4-acetic acid, gamma,4'-dihydroxy(1,1'-biphenyl)-4-butanoic acid and beta, gamma-dyhydroxy(1,1'-biphenyl)-4-butanoic acid.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7192124

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  14 in total

Review 1.  Analgesics and breast-feeding: safety considerations.

Authors:  O Spigset; S Hägg
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

Review 2.  Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.

Authors:  P Netter; B Bannwarth; M J Royer-Morrot
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

3.  Diffusion of oxyphenbutazone into synovial fluid, synovial tissue, joint cartilage and cerebrospinal fluid.

Authors:  A Gaucher; P Netter; G Faure; J P Schoeller; A Gerardin
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Does fenbufen have a large distribution volume or is it subject to extensive presystemic elimination?

Authors:  R K Verbeeck; S M Wallace
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Protein binding of non-steroidal anti-inflammatory drugs in plasma and synovial fluid of arthritic patients.

Authors:  S Wanwimolruk; P M Brooks; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

Review 6.  Acute poisoning due to non-steroidal anti-inflammatory drugs. Clinical features and management.

Authors:  J A Vale; T J Meredith
Journal:  Med Toxicol       Date:  1986 Jan-Feb

7.  Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve.

Authors:  P G Davey; M Charter; S Kelly; T R Varma; I Jacobson; A Freeman; E Precious; J Lambert
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 8.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

Review 9.  Fenbufen: a review of its pharmacological properties and therapeutic use in rheumatic diseases and acute pain.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-01       Impact factor: 9.546

Review 10.  Drugs in human milk. Clinical pharmacokinetic considerations.

Authors:  H C Atkinson; E J Begg; B A Darlow
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.